EP3226841C0 - ANTICANCER COMPOUNDS - Google Patents

ANTICANCER COMPOUNDS

Info

Publication number: EP3226841C0
Authority: EP; European Patent Office
Prior art keywords: anticancer compounds; anticancer; compounds
Prior art date: 2014-12-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

EP15817641.2A

Other languages

German (de)

French (fr)

Other versions

EP3226841B1 (en

EP3226841A1 (en

Inventor

Dennis Martin Hester

Jason Michael Vaughn

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aragon Pharmaceuticals Inc

Original Assignee

Aragon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-05

Filing date

2015-12-03

Publication date

2024-10-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3226841(C0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-12-03 Priority to MA41107A priority Critical patent/MA41107B1/en

2015-12-03 Priority to HRP20241719TT priority patent/HRP20241719T1/en

2015-12-03 Priority to SM20240518T priority patent/SMT202400518T1/en

2015-12-03 Priority to EP24202355.4A priority patent/EP4494636A2/en

2015-12-03 Priority to RS20241412A priority patent/RS66323B1/en

2015-12-03 Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc

2017-10-11 Publication of EP3226841A1 publication Critical patent/EP3226841A1/en

2024-10-09 Publication of EP3226841B1 publication Critical patent/EP3226841B1/en

2024-10-09 Publication of EP3226841C0 publication Critical patent/EP3226841C0/en

2024-10-09 Application granted granted Critical

Status Active legal-status Critical Current

2035-12-03 Anticipated expiration legal-status Critical

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Nutrition Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

EP15817641.2A 2014-12-05 2015-12-03 Anticancer compositions Active EP3226841B1 (en)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
HRP20241719TT HRP20241719T1 (en)	2014-12-05	2015-12-03	ANTITUMORAL MIXTURES
SM20240518T SMT202400518T1 (en)	2014-12-05	2015-12-03	ANTI-CANCER COMPOSITIONS
EP24202355.4A EP4494636A2 (en)	2014-12-05	2015-12-03	Anticancer compositions
RS20241412A RS66323B1 (en)	2014-12-05	2015-12-03	Anticancer compositions
MA41107A MA41107B1 (en)	2014-12-05	2015-12-03	ANTI-CANCER COMPOSITIONS

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14196594		2014-12-05
PCT/US2015/063661 WO2016090098A1 (en)	2014-12-05	2015-12-03	Anticancer compositions

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
EP24202355.4A Division EP4494636A2 (en)	2014-12-05	2015-12-03	Anticancer compositions

Publications (3)

Publication Number	Publication Date
EP3226841A1 EP3226841A1 (en)	2017-10-11
EP3226841B1 EP3226841B1 (en)	2024-10-09
EP3226841C0 true EP3226841C0 (en)	2024-10-09

Family

ID=52006906

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP24202355.4A Pending EP4494636A2 (en)	2014-12-05	2015-12-03	Anticancer compositions
EP15817641.2A Active EP3226841B1 (en)	2014-12-05	2015-12-03	Anticancer compositions

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP24202355.4A Pending EP4494636A2 (en)	2014-12-05	2015-12-03	Anticancer compositions

Country Status (27)

Country	Link
US (3)	US20170360754A1 (en)
EP (2)	EP4494636A2 (en)
JP (2)	JP6937692B2 (en)
KR (2)	KR20200141533A (en)
CN (2)	CN114886852A (en)
AR (1)	AR102926A1 (en)
AU (3)	AU2015358490B2 (en)
BR (1)	BR112017011788A2 (en)
CA (1)	CA2969656A1 (en)
CL (1)	CL2017001371A1 (en)
CO (1)	CO2017005572A2 (en)
CR (1)	CR20170216A (en)
EA (1)	EA201791222A1 (en)
ES (1)	ES2996833T3 (en)
HR (1)	HRP20241719T1 (en)
IL (2)	IL252323B (en)
MA (1)	MA41107B1 (en)
MX (2)	MX2017007203A (en)
NZ (1)	NZ770528A (en)
PH (1)	PH12017500964A1 (en)
PL (1)	PL3226841T3 (en)
RS (1)	RS66323B1 (en)
SG (1)	SG11201704267VA (en)
SM (1)	SMT202400518T1 (en)
TW (2)	TWI754258B (en)
UA (1)	UA120950C2 (en)
WO (1)	WO2016090098A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA037806B1 (en)	2012-09-26	2021-05-24	Арагон Фармасьютикалз, Инк.	Method for the treatment of non-metastatic castrate-resistant prostate cancer
SG11201704267VA (en) *	2014-12-05	2017-06-29	Aragon Pharmaceuticals Inc	Anticancer compositions
WO2016090105A1 (en)	2014-12-05	2016-06-09	Aragon Pharmaceuticals, Inc.	Anticancer compositions
SG11202003402QA (en)	2017-10-16	2020-05-28	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144647A1 (en)	2019-01-10	2020-07-16	Aragon Pharmaceuticals, Inc.	Pharmaceutical composition comprising apalutamide dispersed in apple sauce
BR112021014969A2 (en)	2019-01-30	2021-10-05	Aragon Pharmaceuticals, Inc.	ANTIANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION SENSITIVE PROSTATE CANCER
US20210115517A1 (en)	2019-01-30	2021-04-22	Janssen Pharmaceutica Nv	Methods of treating prostate cancer based on molecular subtypes
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en)	2019-10-22	2021-04-28	Zentiva K.S.	Dosage form of apalutamide
WO2021089649A1 (en)	2019-11-04	2021-05-14	Janssen Pharmaceutica Nv	Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en)	2020-06-05	2021-12-09	Janssen Pharmaceutica Nv	Methods of treating prostate cancer based on molecular subtypes
TW202228794A (en)	2020-09-04	2022-08-01	美商艾瑞岡醫藥公司	Methods for treating prostate cancer
WO2022195407A1 (en)	2021-03-19	2022-09-22	Aragon Pharmaceuticals, Inc.	Methods for treating prostate cancer
WO2023122842A1 (en) *	2021-12-31	2023-07-06	Gador Limitada	Method for preparing apalutamide, synthesis intermediaries, and amorphous solid dispersion containing apalutamide
WO2023152611A1 (en)	2022-02-11	2023-08-17	Aragon Pharmaceuticals, Inc.	Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en)	2022-04-26	2023-11-02	Aragon Pharmaceuticals, Inc.	Approved drug products and methods for treating prostate cancer
WO2024189186A1 (en)	2023-03-16	2024-09-19	Bayer Consumer Care Ag	Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT901786E (en) *	1997-08-11	2007-08-07	Pfizer Prod Inc	Solid pharmaceutical dispersions with enhanced bioavailability
SK15732003A3 (en) *	2001-06-22	2005-01-03	Pfizer Products Inc.	Pharmaceutical compositions comprising low-solubility and/or acid-sensitive drugs and neutralized acidic polymers
SE0103424D0 (en) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
CN1787808A (en) *	2002-02-01	2006-06-14	辉瑞产品公司	Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
EP2656842B1 (en) *	2006-03-27	2016-08-10	The Regents of The University of California	Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2013152342A1 (en) *	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Anti-cancer mtor inhibitor and anti-androgen combination
JP6182209B2 (en) *	2012-06-07	2017-08-16	アラゴンファーマシューティカルズ，インコーポレイテッド	Crystalline form of androgen receptor modulator
EP2888293B1 (en) *	2012-08-24	2019-05-08	Dow Global Technologies LLC	Novel hydroxyalkyl methyl cellulose acetate succinates
CN105358535B (en) *	2012-09-11	2019-01-04	麦迪威森前列腺医疗有限责任公司	The miscellaneous Shandong amine preparation of grace
EA037806B1 (en) *	2012-09-26	2021-05-24	Арагон Фармасьютикалз, Инк.	Method for the treatment of non-metastatic castrate-resistant prostate cancer
SG11201600525XA (en) *	2013-08-12	2016-02-26	Tokai Pharmaceuticals Inc	Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EA037895B1 (en) *	2014-02-05	2021-06-02	Лек Фармасьютикалз Д.Д.	Solid pharmaceutical compositions of androgen receptor antagonists
SG11201704267VA (en) *	2014-12-05	2017-06-29	Aragon Pharmaceuticals Inc	Anticancer compositions

2015
- 2015-12-03 SG SG11201704267VA patent/SG11201704267VA/en unknown
- 2015-12-03 CN CN202210133724.8A patent/CN114886852A/en active Pending
- 2015-12-03 EP EP24202355.4A patent/EP4494636A2/en active Pending
- 2015-12-03 CA CA2969656A patent/CA2969656A1/en active Pending
- 2015-12-03 ES ES15817641T patent/ES2996833T3/en active Active
- 2015-12-03 KR KR1020207035390A patent/KR20200141533A/en not_active Ceased
- 2015-12-03 US US15/533,188 patent/US20170360754A1/en not_active Abandoned
- 2015-12-03 CN CN201580066233.4A patent/CN106999431B/en active Active
- 2015-12-03 PL PL15817641.2T patent/PL3226841T3/en unknown
- 2015-12-03 MA MA41107A patent/MA41107B1/en unknown
- 2015-12-03 NZ NZ770528A patent/NZ770528A/en unknown
- 2015-12-03 RS RS20241412A patent/RS66323B1/en unknown
- 2015-12-03 EP EP15817641.2A patent/EP3226841B1/en active Active
- 2015-12-03 MX MX2017007203A patent/MX2017007203A/en unknown
- 2015-12-03 AU AU2015358490A patent/AU2015358490B2/en active Active
- 2015-12-03 UA UAA201707020A patent/UA120950C2/en unknown
- 2015-12-03 BR BR112017011788A patent/BR112017011788A2/en not_active Application Discontinuation
- 2015-12-03 HR HRP20241719TT patent/HRP20241719T1/en unknown
- 2015-12-03 WO PCT/US2015/063661 patent/WO2016090098A1/en active Application Filing
- 2015-12-03 EA EA201791222A patent/EA201791222A1/en unknown
- 2015-12-03 SM SM20240518T patent/SMT202400518T1/en unknown
- 2015-12-03 JP JP2017529604A patent/JP6937692B2/en active Active
- 2015-12-03 CR CR20170216A patent/CR20170216A/en unknown
- 2015-12-03 KR KR1020177018239A patent/KR102348320B1/en active Active
- 2015-12-04 AR ARP150103982A patent/AR102926A1/en not_active Application Discontinuation
- 2015-12-04 TW TW109112959A patent/TWI754258B/en active
- 2015-12-04 TW TW104140822A patent/TWI702966B/en active
2017
- 2017-05-16 IL IL252323A patent/IL252323B/en active IP Right Grant
- 2017-05-25 PH PH12017500964A patent/PH12017500964A1/en unknown
- 2017-05-29 CL CL2017001371A patent/CL2017001371A1/en unknown
- 2017-06-05 CO CONC2017/0005572A patent/CO2017005572A2/en unknown
- 2017-06-05 MX MX2021013965A patent/MX2021013965A/en unknown
2020
- 2020-04-23 JP JP2020076516A patent/JP7174006B2/en active Active
- 2020-12-29 IL IL279833A patent/IL279833B/en unknown
2021
- 2021-03-30 AU AU2021201979A patent/AU2021201979B2/en active Active
2023
- 2023-03-29 US US18/192,244 patent/US20230233529A1/en not_active Abandoned
- 2023-05-02 AU AU2023202710A patent/AU2023202710A1/en active Pending
2024
- 2024-05-10 US US18/660,698 patent/US20240293374A1/en active Pending

Also Published As

Publication number	Publication date
CO2017005572A2 (en)	2017-09-20
AU2021201979B2 (en)	2023-02-02
TWI702966B (en)	2020-09-01
PH12017500964A1 (en)	2017-10-18
RS66323B1 (en)	2025-01-31
CN114886852A (en)	2022-08-12
CA2969656A1 (en)	2016-06-09
CL2017001371A1 (en)	2018-01-05
AU2015358490B2 (en)	2021-04-08
EP3226841B1 (en)	2024-10-09
CN106999431A (en)	2017-08-01
HRP20241719T1 (en)	2025-02-14
TW201630592A (en)	2016-09-01
US20230233529A1 (en)	2023-07-27
IL279833A (en)	2021-01-31
IL279833B (en)	2022-03-01
IL252323B (en)	2021-04-29
MA41107A (en)	2017-10-10
JP2020143069A (en)	2020-09-10
TW202031248A (en)	2020-09-01
AU2015358490A1 (en)	2017-06-08
JP7174006B2 (en)	2022-11-17
AU2021201979A1 (en)	2021-04-29
KR20170086656A (en)	2017-07-26
US20170360754A1 (en)	2017-12-21
AR102926A1 (en)	2017-04-05
JP2017536398A (en)	2017-12-07
NZ770528A (en)	2024-03-22
WO2016090098A1 (en)	2016-06-09
TWI754258B (en)	2022-02-01
KR20200141533A (en)	2020-12-18
EA201791222A1 (en)	2017-09-29
EP4494636A2 (en)	2025-01-22
MA41107B1 (en)	2025-01-31
CR20170216A (en)	2017-08-30
CN106999431B (en)	2022-03-04
JP6937692B2 (en)	2021-09-22
US20240293374A1 (en)	2024-09-05
KR102348320B1 (en)	2022-01-10
ES2996833T3 (en)	2025-02-13
UA120950C2 (en)	2020-03-10
AU2023202710A1 (en)	2023-05-18
PL3226841T3 (en)	2025-03-03
BR112017011788A2 (en)	2017-12-26
EP3226841A1 (en)	2017-10-11
MX2021013965A (en)	2022-01-04
SMT202400518T1 (en)	2025-01-14
MX2017007203A (en)	2017-08-28
SG11201704267VA (en)	2017-06-29
NZ731963A (en)	2024-03-22
IL252323A0 (en)	2017-07-31

Publication	Publication Date	Title
LT3134402T (en)	2020-07-10	4-AMINO-IMIDAZOCHINOLINE COMPOUNDS
LT3197883T (en)	2020-07-10	NEW COMPOUNDS
DK3183051T3 (en)	2020-06-02	LIQUID-TO-LUFTMEMBRANENERGIVEKSLERE
EP3226841C0 (en)	2024-10-09	ANTICANCER COMPOUNDS
DK3211743T3 (en)	2019-12-16	E-to-network omskiftningsfremgangsmåde
DK3006072T3 (en)	2021-10-25	Karadgang
DK3222714T3 (en)	2019-12-09	PHYTASEMUTANTS
DK3119396T3 (en)	2021-05-31	MUSCARINRECEPTORAGONISTER
DK3226842T3 (en)	2021-01-25	ANTICANCER COMPOSITIONS
EP3230438C0 (en)	2024-12-04	N-GLYCOLISATION
DK3226843T3 (en)	2021-08-16	ANTICANCER COMPOSITIONS
DE112015001664A5 (en)	2016-12-29	Betätigungsaktuator
CL2016002165A1 (en)	2017-06-09	Aminocarbonylcarbamate compounds
BR112016030730A2 (en)	2017-08-22	Compound
DK3183340T3 (en)	2019-08-19	TERMOLABILE EXONUCLEASER
DK3191466T3 (en)	2020-01-20	AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS
DK3154703T3 (en)	2020-11-16	FULLKAPPE-SNEKKECENTRIFUGE
DK3110439T3 (en)	2019-05-13	PCSK9-VACCINES
HUE039805T2 (en)	2019-02-28	New sulfonylaminobenzamide compounds
DE112015005041A5 (en)	2017-08-31	GARGERÄTEVORRICHTUNG
IL253276A0 (en)	2017-08-31	Anticancer compounds
DE102014000623A8 (en)	2016-10-13	Halbhohlnietelement
EP3298005C0 (en)	2024-01-24	ANTICANCER COMPOUNDS
DK3009858T3 (en)	2021-08-09	SKYRADAR
ES2697898T8 (en)	2019-02-15	Tricyclic tricyclic compounds

Legal Events

Date	Code	Title	Description
2015-12-03	REG	Reference to a national code	Ref country code: HR Ref legal event code: TUEP Ref document number: P20241719T Country of ref document: HR
2017-06-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2017-09-08	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2017-09-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2017-10-11	17P	Request for examination filed	Effective date: 20170705
2017-10-11	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2017-10-11	AX	Request for extension of the european patent	Extension state: BA ME
2018-09-28	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-10-31	17Q	First examination report despatched	Effective date: 20181001
2019-11-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-01-27	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ARAGON PHARMACEUTICALS, INC.
2021-07-07	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ARAGON PHARMACEUTICALS, INC.
2021-07-14	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: ARAGON PHARMACEUTICALS, INC.
2023-04-17	TPAC	Observations filed by third parties	Free format text: ORIGINAL CODE: EPIDOSNTIPA
2023-07-12	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230531
2023-10-31	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Ref document number: 602015090101 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0009140000 Ipc: A61K0031418400 Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61K0009140000 Ipc: A61K0031418400
2023-11-16	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2023-11-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2023-12-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 9/20 20060101ALI20231031BHEP Ipc: A61K 9/14 20060101ALI20231031BHEP Ipc: A61P 35/00 20060101ALI20231031BHEP Ipc: A61K 31/4184 20060101AFI20231031BHEP
2023-12-13	INTG	Intention to grant announced	Effective date: 20231117
2024-03-19	GRAJ	Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted	Free format text: ORIGINAL CODE: EPIDOSDIGR1
2024-03-19	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2024-04-24	INTC	Intention to grant announced (deleted)
2024-05-01	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2024-05-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2024-05-29	INTG	Intention to grant announced	Effective date: 20240502
2024-09-02	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2024-09-06	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2024-09-06	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE PATENT HAS BEEN GRANTED
2024-10-09	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2024-10-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2024-10-24	REG	Reference to a national code	Ref country code: DE Ref legal event code: R096 Ref document number: 602015090101 Country of ref document: DE
2024-11-06	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2024-12-18	U01	Request for unitary effect filed	Effective date: 20241108
2025-01-01	P04	Withdrawal of opt-out of the competence of the unified patent court (upc) registered	Free format text: CASE NUMBER: APP_62748/2024 Effective date: 20241125
2025-01-01	U07	Unitary effect registered	Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20241127
2025-01-08	U20	Renewal fee paid [unitary effect]	Year of fee payment: 10 Effective date: 20241205
2025-01-14	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: MC Payment date: 20241212 Year of fee payment: 10
2025-01-17	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: GB Payment date: 20241212 Year of fee payment: 10
2025-01-23	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IS Payment date: 20241227 Year of fee payment: 10
2025-01-24	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: IE Payment date: 20241209 Year of fee payment: 10
2025-01-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: RS Payment date: 20241220 Year of fee payment: 10 Ref country code: SM Payment date: 20241219 Year of fee payment: 10
2025-01-31	REG	Reference to a national code	Ref country code: MA Ref legal event code: VAGR Ref document number: 41107 Country of ref document: MA Kind code of ref document: B1
2025-02-03	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: TR Payment date: 20241209 Year of fee payment: 10
2025-02-12	RAP4	Party data changed (patent owner data changed or rights of a patent transferred)	Owner name: ARAGON PHARMACEUTICALS, INC.
2025-02-12	U1H	Name or address of the proprietor changed [after the registration of the unitary effect]	Owner name: ARAGON PHARMACEUTICALS, INC.; US
2025-02-13	REG	Reference to a national code	Ref country code: ES Ref legal event code: FG2A Ref document number: 2996833 Country of ref document: ES Kind code of ref document: T3 Effective date: 20250213
2025-02-14	REG	Reference to a national code	Ref country code: HR Ref legal event code: T1PR Ref document number: P20241719 Country of ref document: HR
2025-02-26	REG	Reference to a national code	Ref country code: SK Ref legal event code: T3 Ref document number: E 45658 Country of ref document: SK
2025-02-28	PGFP	Annual fee paid to national office [announced via postgrant information from national office to epo]	Ref country code: HU Payment date: 20241218 Year of fee payment: 10
2025-02-28	REG	Reference to a national code	Ref country code: HR Ref legal event code: ODRP Ref document number: P20241719 Country of ref document: HR Payment date: 20250206 Year of fee payment: 10
2025-03-06	REG	Reference to a national code	Ref country code: GR Ref legal event code: EP Ref document number: 20250400025 Country of ref document: GR Effective date: 20250211